Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, Casirivimab & Imdevimab, Remdesivir, Favipravir
Eligibility Criteria
Inclusion Criteria:
- age more than 12 years old.
- weight not less than 40 kg.
- Moderate, sever or critical COVID-19 disease as defined by WHO.
- PCR- confirmed patients to be Positive before inclusion.
Exclusion Criteria:
- history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.
- prior use of standard antiviral therapy (remedsvir or favipravir).
- Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltemavir, acyclovir, ribavirine, lopinvir/rotinvir, sofosfbuvir, decltasevir, semipirvir, azithromycin).
- patients expected to die within 48 hours.
Sites / Locations
- El-gomhoria St
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
casirivimab and imdevimab
Remdesivir
Favipravir
casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.
Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes
Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours